Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis.

Authors

Andrew P Jallouk, Lorenzo Falchi, Ayushi Chauhan, Geoffrey Shouse, Swetha K Thiruvengadam, Yazeed Sawalha, Sonia Godbole, Ajay Major, Reid W Merryman, Shakthi T Bhaskar, Allison M Bock, Mehdi Hamadani, Amy Ayers, Omnia Farahat, Narendranath Epperla, Jennifer L Crombie, Steven Bair, Mathew A Lunning, Alex F Herrera, Christopher R Flowers, Gilles Salles, Sairah Ahmed

Published in

Blood neoplasia. Volume 3. Issue 4. Pages 100280. Epub Jul 28, 2026.

Abstract

Mosunetuzumab (mosun) is a CD20 × CD3 bispecific antibody approved for follicular lymphoma. Despite promising results in clinical trials, there are limited real-world data to assess outcomes with mosun, particularly in patients with poor performance status or significant comorbidities. To address this need, we performed a multicenter retrospective study at 9 centers in the Collaborative US Bispecifics Consortium and identified 119 patients who received mosun for non-Hodgkin lymphoma. Ninety patients (75.6%) had indolent lymphomas, 26% of whom would not have been eligible for the mosun registrational trial. Of these patients, 97% received single-agent mosun. Overall response rate was 87%, and the complete response rate was 71%. With a median follow-up of 17.0 months, median progression-free survival (PFS) and overall survival (OS) were not reached. Eighteen-month PFS and OS estimates were 56.7% and 92.9%, respectively. Most cases of cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome were low grade, with no differences in survival between trial-eligible and trial-ineligible patients. There was a higher rate of infections in trial-ineligible patients than in trial-eligible patients (45% vs 21%; P = .043). These findings support the use of mosun in the treatment of relapsed/refractory indolent lymphomas, even in trial-ineligible patients.

PMID:
42893203
Bibliographic data and abstract were imported from PubMed on 18 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.